Form 4: Aadi Bioscience Director Caley Castelein Reports Significant Share Acquisition

Director Caley Castelein reports acquiring 1,666,000 shares of Aadi Bioscience, Inc. common stock on March 4, 2025, at a price of $2.4 per share.

Summary

• On March 4, 2025, Caley Castelein, a director of Aadi Bioscience, Inc., reported acquiring 1,666,000 shares of common stock.
• The shares were purchased at a price of $2.4 per share.
• Following the transaction, Castelein directly owns 19,694 shares and indirectly owns 2,165,998 shares.
• The indirect ownership is through KVP Capital, LP, where Castelein serves as Managing Director.
• Castelein disclaims beneficial ownership of shares held by KVP Capital, except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director increasing their stake in the company is generally viewed favorably, but the filing itself is a routine disclosure.

Positives

• A director's purchase of a significant number of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Management Comments

• The Reporting Person disclaims beneficial ownership of shares held by KVP Capital, except to the extent of their pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive sign.

Key Dates